Janux Therapeutics, Inc. (JANX)
US — Healthcare Sector
Automate Your Wheel Strategy on JANX
With Tiblio's Option Bot, you can configure your own wheel strategy including JANX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JANX
- Rev/Share 0.1511
- Book/Share 16.3852
- PB 1.563
- Debt/Equity 0.0223
- CurrentRatio 58.4698
- ROIC -0.1097
- MktCap 1515476872.0
- FreeCF/Share -0.7531
- PFCF -32.5671
- PE -20.3556
- Debt/Assets 0.0215
- DivYield 0
- ROE -0.0929
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | JANX | Raymond James | -- | Outperform | -- | $65 | July 11, 2025 |
| Reiterated | JANX | BTIG Research | -- | Buy | $82 | $100 | Dec. 3, 2024 |
| Reiterated | JANX | H.C. Wainwright | -- | Buy | $63 | $70 | Dec. 3, 2024 |
| Initiation | JANX | Stifel | -- | Buy | -- | $70 | Sept. 6, 2024 |
News
About Janux Therapeutics, Inc. (JANX)
- IPO Date 2021-06-11
- Website https://www.januxrx.com
- Industry Biotechnology
- CEO David Alan Campbell
- Employees 91
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.